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Background: The availability of HIV antiretroviral therapy (ART) has been associated with the development of
transmitted drug resistance-associated mutations (TDRM). TDRM can compromise treatment effectiveness in patients
initiating ART and the prevalence can vary in different clinical settings. In this study, we investigated the proportion
of TDRM in treatment-naïve, recently infected HIV-positive individuals sampled from four urban locations across Asia
between 2007–2010.
Methods: Patients enrolled in the TREAT Asia Studies to Evaluate Resistance – Surveillance Study (TASER-S) were
genotyped prior to ART initiation, with resulting resistance mutations analysed according to the WHO 2009 list.
Results: Proportions of TDRM from recently infected individuals from TASER-S ranged from 0% to 8.7% - Hong Kong:
3/88 (3.4%, 95% CI (0.71%-9.64%)); Thailand: Bangkok: 13/277 (4.7%, 95% CI (2.5%-7.9%)), Chiang Mai: 0/17 (0%, 97.5% CI
(0%-19.5%)); and the Philippines: 6/69 (8.7%, 95% CI (3.3%-18.0%)). There was no significant increase in TDRM over time
across all four clinical settings.
Conclusions: The observed proportion of TDRM in TASER-S patients from Hong Kong, Thailand and the Philippines
was low to moderate during the study period. Regular monitoring of TDRM should be encouraged, especially with the
scale-up of ART at higher CD4 levels.
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Since 2001, the World Health Organization (WHO) has
been promoting a public-health approach to improve
access to antiretroviral therapy (ART) in resource-
limited settings [1]. With the scale up of ART, patients
who experienced virological failure or those who failed
to suppress the virus may continue to have ongoing viral
replication under drug pressure which increases the risk
of the development of resistance-associated mutations
(RAMs). These RAMs may further compromise future
treatment outcomes and can be transmitted, leading to pri-
mary drug resistance in other un-treated individuals [2,3].* Correspondence: ajiamsakul@kirby.unsw.edu.au
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unless otherwise stated.In resource-limited countries in Asia, non-nucleoside
reverse transcriptase inhibitors (NNRTI) is predomin-
antly used in standard first-line therapy. A Thai study
reported a 2% prevalence of transmitted drug resistance-
associated mutations (TDRM) in recently HIV-infected
patients, with the annual proportion rising from 0% to
5.2% between 2003–2006. The most common RAMs
found in this study were M184V and Y181C reflecting
lamivudine and NNRTI resistance [4]. Hong Kong SAR
China, a high-income locality, reported a TDRM preva-
lence of 3.6% between 2003–2007, with the protease
inhibitors (PI) RAMs (M46I/L and L33F) being the most
common mutations consistent with widespread use of
PI-based initial regimen [5]. Conversely, an Australian
study found rates of TDRM to have dropped dramatically
after the introduction of combination ART in 1996 [6].ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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TDRM in treatment-naïve, recently infected HIV-positive
individuals in selected Therapeutics, Research, Education,
and AIDS Training in Asia (TREAT Asia) sites, and to
determine changes in proportion of TDRM over time.
The reported findings may not be representative of the
broader Asia-Pacific region, but rather of those who
participated in the study.
Methods
Treatment-naïve, recently HIV-infected patients were
recruited into the TREAT Asia Studies to Evaluate
Resistance – Surveillance Study (TASER-S) between
2007-2010 [7] from 5 participating sites: 2 from Hong
Kong SAR, China; 1 from Bangkok, Thailand; 1 from
Chiang Mai, Thailand; and 1 from Manila, Philippines.
Patients were included in TASER-S according to the
following inclusion criteria:
Hong Kong SAR, China: patients were selected from
those who attended the two participating clinics and satis-
fied one of these criteria: (a) age up to 25 years old; (b)
negative HIV test within one year; or (c) BED assay positive.
Bangkok, Thailand: patients were enrolled from a vol-
untary counselling and testing centre in Bangkok. All modes
of HIV exposure were considered, however male patients
with homosexual HIV exposure were selectively chosen to
be enrolled in 2010. Recent HIV infection was defined as a
new HIV diagnosis in subjects <25 years old. For those who
were older, previous HIV-negative documentation within
the past 12 months was required for study inclusion.
Chiang Mai, Thailand: patients presented to care at
the participating hospital were selected for enrolment.
Patients were included if they had a confirmed HIV-
positive test and were aged <25 years with no prior
AIDS-defining illnesses.
Manila, Philippines: blood samples were obtained
from the STD AIDS Cooperative Central Laboratory, the
National Reference Laboratory for HIV and Other STIs
(NRL-SACCL). All samples obtained from asymptomatic
patients were tested using the BED assay. Those with
positive BED tests were presumed to be recently infected
and included in TASER-S.
CD4 count was not used as a criteria in TASER-S as
the study protocol was developed prior to the WHO
2008 surveillance recommendations [8], and it was not
known a priori the time lag for obtaining CD4 results.
Genotyping was performed at TREAT Asia Quality
Assessment Scheme (TAQAS) certified laboratories [9].
Pre-treatment pol gene FASTA files were submitted to
the Stanford University HIV Drug Resistance Database[10] Version 6.2 for genotyping and REGA HIV-1 Subtyp-
ing Tool [11,12] - Version 2.0 for subtyping. RAMs were
analysed according to the WHO 2009 list [13]. TDRM
was defined as having ≥1 RAM. Patients with both prote-
ase (PR) and reverse transcriptase (RT) sequences avail-
able were included.
Clinical characteristics, including age, sex, mode of HIV
exposure, viral load, CD4 count and HIV-1 subtype, were
reported descriptively. Time trends were analysed using
chi-squared test for trend. Confidence intervals (CI) for
proportion of RAMs were calculated using the exact bino-
mial methods. A sensitivity analysis was performed by
including patients who were missing a PR or RT sequence
file by assuming an absence of RAMs in the missing gene
region and also by including those with extensive RAMs
without confirmation of their treatment naïve status. All
data management and statistical analyses were performed
using SAS software version 9.3 (SAS Institute Inc., Cary,
NC, USA) and STATA software version 12.1 (STATA
Corp., College Station, TX, USA).
Data transfers were aggregated at The Kirby Institute,
UNSW Australia. Ethics approvals were obtained from
UNSW Australia Ethics Committee and institutional re-
view boards at the participating clinical sites and coordin-
ating centre (TREAT Asia/amfAR, Bangkok, Thailand).
Written informed consent was obtained from participants
prior to enrolment – except in the Philippines, where
anonymous samples were obtained from the NRL-SACCL
and consent was waived.
Results
Hong Kong SAR, China
A total of 88 patients were included from the 2 sites
(Table 1). The overall proportion was 3/88 (3.4%, 95% CI
(0.71%-9.64%)). Figure 1 shows TDRM in 2007 was 0/28
(0.0%); 2008: 2/32 (6.3%); 2009: 1/21 (4.8%); and 2010: 0/7
(0.0%), p-trend = 0.631.
Table 2 shows a list of RAMs harboured by different
individuals. Of the 3 patients with RAMs from Hong
Kong, 1 patient had a PR RAM (M46I) and 2 patients
had one RT RAM each (K103N and M41L).
Bangkok, Thailand
Recruitment occurred between 2008–2010 with a total of
277 patients. TDRM was present in 13/277 (4.7%, 95% CI
(2.5%-7.9%)). The proportions of TDRM by year were:
2008: 4/118 (3.4%); 2009: 4/83 (4.8%); and 2010: 5/76
(6.6%), p-trend = 0.305 (Figure 1). The most common
PR-RAM was M46I (6 patients) and the most common
RT-RAM was Y181C (3 patients) (Table 2).
Chiang Mai, Thailand
Seventeen patients were enrolled into the study during
the years 2007 (4 patients), 2008 (10 patients) and 2009
Table 1 Patient characteristics
Hong Kong Bangkok, Thailand Chiang Mai, Thailand Manila, Philippines
Total = 88 (%) Total = 277 (%) Total = 17 (%) Total = 69 (%)
Without
TDRM= 85 (96.6)
With
TDRM = 3 (3.4)
Without
TDRM= 264 (95.3)
With TDRM = 13 (4.7) Without
TDRM = 17 (100.0)
Without
TDRM = 63 (91.3)
With
TDRM= 6 (8.7)
Age (years) Median = 29 Median = 42 Median = 23 Median = 23 Median = 22 Median = 25 Median = 30.5
IQR (24–37) IQR (32–56) IQR (21–24) IQR (20–25) IQR (21–23) IQR (23–28) IQR (25–33)
<25 25 (29.4) 0 (0.0) 207 (78.4) 9 (69.2) 17 (100.0) 28 (44.4) 1 (16.7)
25-34 30 (35.3) 1 (33.3) 47 (17.8) 4 (30.8) 0 (0.0) 34 (54.0) 4 (66.7)
35-44 21 (24.7) 1 (33.3) 7 (2.7) 0 (0.0) 0 (0.0) 1 (1.6) 1 (16.7)
≥45 9 (10.6) 1 (33.3) 3 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Sex
Male 81 (95.3) 3 (100.0) 247 (93.6) 13 (100.0) 12 (70.6) 54 (85.7) 5 (83.3)
Female 4 (4.7) 0 (0.0) 17 (6.4) 0 (0.0) 5 (29.4) 9 (14.3) 1 (16.7)
HIV exposure
Heterosexual contact 9 (10.6) 0 (0.0) 30 (11.4) 1 (7.7) 10 (58.8) 9 (14.3) 1 (16.7)
Homosexual contact 72 (84.7) 3 (100.0) 229 (86.7) 11 (84.6) 7 (41.2) 39 (61.9) 3 (50.0)
Bisexual 4 (4.7) 0 (0.0) 4 (1.5) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0)
Injecting drug use 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Other/Unknown 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (3.2) 0 (0.0)
Viral load (copies/ml) Median = 77000 Median = 46000 Median = 41790 Median = 170000 Median = 75001 N/A N/A
IQR (20261–220000) IQR (59000–68000) IQR (16208–130000) IQR (17414–360000) IQR (39375–80119)
≤50000 36 (42.4) 2 (66.7) 144 (54.5) 6 (46.2) 7 (41.2) 0 (0.0) 0 (0.0)
50001-250000 28 (32.9) 1 (33.3) 84 (31.8) 1 (7.7) 10 (58.8) 0 (0.0) 0 (0.0)
250001+ 21 (24.7) 0 (0.0) 35 (13.3) 6 (46.2) 0 (0.0) 0 (0.0) 0 (0.0)
Missing 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 63 (100.0) 6 (100.0)
CD4 (cells/uL) Median = 408.5 Median = 348 Median = 342 Median = 370.5 Median = 308 N/A N/A
IQR (267–552) IQR (315–641) IQR (255–479) IQR (271–438) IQR (103–405.5)
≤50 4 (4.7) 0 (0.0) 5 (1.9) 0 (0.0) 4 (23.5) 0 (0.0) 0 (0.0)
51-100 1 (1.2) 0 (0.0) 6 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
101-200 4 (4.7) 0 (0.0) 20 (7.6) 1 (7.7) 1 (5.9) 0 (0.0) 0 (0.0)
201-500 44 (51.8) 2 (66.7) 128 (48.5) 8 (61.5) 10 (58.8) 0 (0.0) 0 (0.0)
>500 25 (29.4) 1 (33.3) 46 (17.4) 1 (7.7) 1 (5.9) 0 (0.0) 0 (0.0)
Missing 7 (8.2) 0 (0.0) 59 (22.3) 3 (23.1) 1 (5.9) 63 (100.0) 6 (100.0)
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Table 1 Patient characteristics (Continued)
Subtype
CRF01_AE 24 (28.2) 0 (0.0) 218 (82.6) 11 (84.6) 14 (82.4) 22 (34.9) 2 (33.3)
B 52 (61.2) 3 (100.0) 22 (8.3) 1 (7.7) 2 (11.8) 24 (38.1) 3 (50.0)
Other 9 (10.6) 0 (0.0) 24 (9.1) 1 (7.7) 1 (5.9) 17 (27.0) 1 (16.7)
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Figure 1 Proportion of transmitted drug-resistance mutations (TDRM).
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one-sided CI of (0%-19.5%).
Manila, Philippines
Blood samples were collected from 69 patients. TDRM
was present in 6/69 patients (8.7%, 95% CI (3.3%-18.0%)).
Figure 1 shows in 2008, 0/1 patients (0.0%) had TDRM;
2009: 6/67 (9.0%); and 2010: 0/1 (0.0%), p-trend >0.999.
Out of the 6 patients who harboured RAMs, all but
one harboured only one resistance mutation (Table 2).
Sensitivity analysis
With the inclusion of 5 patients with missing RT region
and 3 patients with extensive mutations from Bangkok,
the total proportion of TDRM for this site increased to
5.6% with 95% CI (3.2%-9.0%). The yearly trend of TDRM
was not significant at p = 0.256. For Manila, the inclusion
of 13 patients with missing PR or RT sequences increased
the proportion to 7/82 (8.5%, 95% CI (3.5%-16.8%)),
p-trend = 0.860.
Discussion
Observed proportions of TDRM in this study ranged from
0% to 8.7%, with no significant increase in trend over time.
TASER-S participants were predominantly men who have
sex with men (MSM). Studies have shown that MSM was
associated with the presence of TDRM with higher rates
of resistance reported in this group [5,14]. Although each
TASER-S site utilised a different recruitment strategy
which prevents direct comparison of TDRM across sites,
the findings of this study suggests that the Philippines, acountry that has not yet encountered a national epidemic
comparable to other Southeast Asian countries [15], had a
relatively higher TDRM proportion of 8.7%. This could be
due to other non-B subtypes [16] prevalent in the sample
(26.1%) and may warrant further investigation into the ex-
tent of HIV RAMs within the country and the associated
key population at risk.
The proportion of TDRM for Hong Kong (3.4%) and
Bangkok (4.7%) were similar to that found previously [5,17]
although there were differences in the sample sizes and
sampling methodology. Chiang Mai reported 0% TDRM,
but given that only 17 patients were enrolled, it is not pos-
sible to exclude drug resistance prevalence as high as 19.5%.
Our study had several limitations including the potential
sampling bias within the study. TASER-S included only pa-
tients attending TREAT Asia sites. Informed consent was
required from all participants, except in the Philippines,
and this may further contribute to sampling bias by allow-
ing only those who consented to be included in the study.
Other limitations were the possibility of patients experien-
cing reversion of RAMs back to wild-type [18,19]; and the
possibility of misclassification by BED assay due to its high
false recent rates [20], although this only applies to patients
recruited from Hong Kong and the Philippines. Findings of
TDRM reported in this study only reflect those participat-
ing in TASER-S and may not be generalisable to the
broader HIV-infected population across the region.
Conclusions
In summary, the observed proportion of TDRM in
TASER-S patients from Hong Kong, Thailand and the
Table 2 Protease (PR) and Reverse Transcriptase (RT)
Mutations
Site Patient PR mutations RT mutations
Hong Kong
SAR, China
1 M46I
2 K103N
3 M41L
Bangkok,
Thailand
4 M46I + V82A
5 M46I
6 M46I
7 L24I
8 T215D
9 V82F
10 K103N
11 K103N
12 Y181C + T215I + K219E
13 M46I + I54V +
I84V + L90M
M184V
14 M46I Y181C + T215F
15 Y181C +M184V
16 M46I
a D67G + K70R + K103N +
Y181C +M184V + T215I + K219E
b L74V + F116Y + Q151M +
Y181C +M184I + G190A
c M41L + T69D + V75M +
Y181C +M184V + T215Y
Manila,
Philippines
17 L23I
18 K70R
19 I84V
20 G73S + N88D
21 M41L
22 L23I
d V106A
Note: patients a, b, c and d were those included in the sensitivity analysis for
Bangkok, Thailand and Manila, Philippines.
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With the 2013 WHO guidelines recommending ART initi-
ation in persons with CD4 count ≤500 cells/μL [21], and
the possible scale-up of ART due to “Test and Treat” strat-
egies [22], further monitoring of acquired drug resistance
in individuals on ART, as well as regular surveillance of re-
cently infected persons should be encouraged.
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